« What Really Makes a Biopharma Hub? |
| Open Access For ACS Articles? »
March 5, 2013
TauRx's Funding Is Odd
I still get inquiries about TauRx and their work on Alzheimer's. There's an awful lot of pent-up demand in that field, and it's getting worse every year. The latest is that the company has ten million more dollars in a follow-on investment option from the Dundee Corporation of Toronto.
Who they? That's what I wondered, too, and the press release occasions more questions than it answers:
Dundee Corporation is a Canadian independent publicly traded asset management company listed on the Toronto Stock Exchange (“TSX”) under the symbol “DC.A”. Asset management activities are focused in the areas of the corporation’s core competencies and include resources, real estate and infrastructure, and more recently, the agriculture sector.
What, then, are they doing investing in biopharma? You can lose your shirt over here, guys, and you can most especially lose it in Alzheimer's. TauRx also has major funding from the Genting Burhad group. And you may well ask "Who they?", too, because they're a large Malaysian company whose core business is casinos and resorts. Now, they're also into cruise ships, and oil and gas, and power generation and (perforce) real estate, but biotech would seem to be rather far down the list.
This is a. . .unique funding setup for a biopharma company. I have to think that there's a reason for it, but I'm not quite sure what the reason is. Speculation, anyone? Thanks to John Carroll of FierceBiotech on Twitter, who doesn't understand what's going on, either.
+ TrackBacks (0) | Category: Alzheimer's Disease | Business and Markets
POST A COMMENT
- RELATED ENTRIES
- Why Not Share More Bioactivity Data?
- An Anticoagulant Antidote
- Merck's Liptruzet: A Cause For Shame?
- Your Brain Shifts Gears
- Total Synthesis in Print
- Things I Won't Work With: Dimethylcadmium
- Another Germ Theory Victory - Back Pain?
- An Update on Deuterium Drugs